Does increased platelet release of Aβ peptide contribute to brain abnormalities in individuals with depression?

Medical Hypotheses

Volumn 60, Issue 5, 2003, Pages 640-643

  Pomara, Nunzio ^a,b   Murali Doraiswamy, P ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; PEPTIDE;

ARTICLE; BETA CHAIN; BRAIN DISEASE; COGNITIVE DEFECT; HUMAN; HYPOTHESIS; MAJOR DEPRESSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RECURRENT DISEASE; RISK; THROMBOCYTE ACTIVATION; VASCULAR AMYLOIDOSIS;

EID: 0037402999     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00380-8     Document Type: Article

References (44)

1. Lloyd A., Grace J. B., Jaros E. et al. Depression in late life, cognitive decline and white matter pathology in two clinico-pathologically investigated cases. Int J Geriatr Psychiatry 2001; 16: 281-287.
2. Lai T., Payne M. E., Byrum C. E., Steffens D. C., Krishnan K. R. Reduction of orbital frontal cortex in geriatric depression. Biol Psychiatry 2000; 48: 971-975.
3. Palsson S., Aevarsson O., Skoog I. Depression, cerebral atrophy, cognitive performance and incidence of dementia. Population study of 85-year-olds. Br J Psychiatry 1999; 174: 249-253.
4. Greenwald B. S., Kramer-Ginsberg E., Bogerts B. et al. Qualitative magnetic resonance imaging finding in geriatric depression: Possible link between later-onset depression and Alzheimer's disease? Psychol Med 1997; 27: 31-42.
5. Palsson S., Larsson L., Tengelin E. et al. The prevalence of depression m relation to cerebral atrophy and cognitive performance in 70- and 74-year-old women in Gothenburg. The women's health study. Psychol Med 2001; 31: 39-49.
6. Zubenko G. S., Sullivan P., Nelson J. P., Belle S. H., Huff F. J., Wolf G. L. Brain imaging abnormalities in mental disorders of late life. Arch Neurol 1990; 47: 1107-1111.
7. Speck C. E., Kukull W. A., Brenner D. et al. History of depression as a risk factor for Alzheimer's disease. Epidemiology 1995; 6: 366-369.
8. Devanand D. P., Sano M., Tang M. X. et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996; 53: 175-182.
9. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr Scand 1997; 96: 157-168.
10. Drevets W. C. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813-829.
11. Hickie I., Scott E., Naismith S. et al. Late-onset depression: Genetic, vascular and clinical contributions. Psychol Med 2001; 31: 1403-1412.
12. Krisknan K. R. R., McDonald W. M., Doraiswamy P. M. et al. Neuroanatomical substrates of depression in the elderly. Eur Arch Psychiatry Clin Neurosci 1993; 243: 41-46.
13. Rajkowska G., Miguel-Hidalgo J. J., Wei J. et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085-1098.
14. Kumar A., Newberg A., Alavi A., Berlin J., Smith R., Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer's disease: a preliminary positron emission tomography study. Proc Natl Acad Sci 1993; 90: 7019-7023.
15. Alexopoulos G. S., Meyers B. S., Young R. C., Kakuma T., Silbersweig D., Charlson M. Clinically defined vascular depression. Am J Psychiatry 1997; 154: 562-565.
16. Krishnan K. R. R., Hays J. C., Blazer D. G. MRI-Defined Vascular Depression. Am J Psychiatry 1997; 154: 497-501.
17. Sheline Y. I., Sanghavi M., Mintun M. A., Gado M. H. Depression duration but not age predicts hippocampal volume loss in medically health women with recurrent major depression. J Neurosci 1999; 19: 5034-5043.
18. Sheline Y. I., Wang P. W., Gado M. H., Csernansky J. G., Vannier M. W. Hippocampal atrophy in recurrent major depression. Med Sci 1996; 93: 3908-3913.
19. Musselman D. L., Tomer A., Manatunga A. K. et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153: 1313-1317.
20. Musselman D. L., Marzec U. M., Manatunga A. Platelet reactivity in depressed patients treated with paroxetine. Arch Gen Psychiatry 2000; 57: 875-882.
21. Lagrhrissi-Thode F., Wagner W. R., Pollock B. G. Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; 42: 290-295.
22. Pollock B. G., Laghrissi-Thode F., Wagner W. R. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20: 137-140.
23. Markovitz J. H., Shuster J. L., Chitwood W. S., May R. S., Tolbert L. C. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000; 157: 1006-1008.
24. Lederbogen F., Gilles M., Maras A. et al. Increased platelet aggregability in major depression? Psychiatry Res 2001; 102: 255-261.
25. Piletz J. E., Zhu H., Madakasira S. Elevated p-selectin on platelets in depression: response to bupropion. J Psychiatr Res 2000; 34: 397-404.
26. Whyte E. M., Pollock B. G., Wagner W. R. et al. Influence of serotonin-transponer linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001; 158: 2074-2076.
27. Berk M., Plein H. Platelet susceptibility to thrombin stimulation in depression: a possible mechanism for the association with cardiovascular mortality. Clin Neuropharmacol 2000; 23: 182-185.
28. Van Nostrand W. E., Schmaier A. H., Farrow J. S., Cines D. B., Cunningham D. D. Protease nexin-2/amyloid β protein precursor in blood is a platelet-specific protein. Biochem Biophys Res Commun 1991; 175: 15-21.
29. Li Q. X., Berndt M. C., Bush A. I. et al. Membrane-associated forms of the βA4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: Surface expression on the activated human platelet. Blood 1994; 84: 133-142.
30. Smith R. P., Broze G. J. Characterization of platelet-releasable forms of β-amyloid precursor proteins: the effect of thrombin. Blood 1992; 80: 2252-2260.
31. Di Luca M., Colciaghi F., Pastorino L., Borroni B., Padovani A., Cattabeni F. Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer's disease: the case of amyloid precursor protein. Eur J Pharm 2000; 405: 277-283.
32. Skovronsky D. M., Lee V. M. Y., Pratico D. Amyloid precursor protein and amyloid β peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 2001; 276: 17036-17043.
33. Joseph R., Tsering C., Welch K. M. A. Study of platelet-mediated neurotoxicity in rat brain. Stroke 1992; 23: 394-398.
34. Joseph R., Tsering C., Grunfeld S., Welch K. M. A. Platelet secretory products may contribute to neuronal injury. Stroke 1991; 22: 1448-1451.
35. Zlokovic B. V., Ghiso J., Mackic J. B., McComb J. G., Weiss M. H., Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun 1993; 197: 1034-1040.
36. Mayeux R., Tang M. X., Jacobs D. M. et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999; 46: 412-416.
37. Mehta P. D., Dalton A. J., Mehta S. P., Kim K. S., Sersen E. A., Wisniewski H. M. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 1998; 241: 13-16.
38. Tokuda T., Fukushima T., Ikeda S. et al. Plasma levels of amyloid beta proteins Abetal-40 and Abeta1-42 (43) are elevated in Down's syndrome. Ann Neurol 1997; 41: 271-273.
39. Schupf N., Patel B., Silverman W. et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001; 301: 199-203.
40. Scheuner D., Eckman C., Jensen M. et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 850-852.
41. Eckman C. B. Presenilins and Alzheimer's disease: the role of A β 42. J Neural Transm Suppl 1998; 53: 181-184.
42. Abraham I., Harkany T., Horvath K. M. et al. Chronic corticosterone administration dose-dependently modulates Aβ (1-42)- and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis. J Neuroendocrinol 2000; 12: 486.
43. O'Brien J., Thomas A., Ballard C. et al. Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology. Biol Psychiatry 2001; 49: 130-136.
44. Sauer W. H., Berlin J. A., Kimmel S. E. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-1898.